Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Eli Lilly shares are now positive for the year, up 10% since the start of January.

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration will not finalize a Biden-era plan to require coverage of anti-obesity medications in Medicare and Medicaid. In a rule finalized Friday afternoon, the Centers for Medicare ...

Also Read: Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech ... A decision is anticipated in 2025. Price Action: Novo Nordisk stock is down 2.06% at $67.87 during ...

That makes the species, also known as the Asian house shrew, an early stop for developers of next-generation weight-loss drugs: If the shrew gets a dose and doesn't barf, there's a good chance ...